News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genentech (RHHBY) and Biogen Idec, Inc. (Massachusetts) (BIIB) Refused a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case


7/16/2013 9:49:50 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Copenhagen, Denmark; July 15, 2013 – Genmab A/S (OMX: GEN) announced today that the U.S. Court of Appeals for the Federal Circuit has declined the request for re-hearing. The court upheld its judgment in favor of GlaxoSmithKline (GSK) in the patent infringement case involving Arzerra® brought against GSK by Genentech and Biogen Idec.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES